Current Setup & Catalysts

Where we are right now

A 26.7% growth year and the first non-GAAP profit since the IPO bust were already on the tape when Yatsen reset the entire near-term debate in March-May 2026: a related-party US$120M convertible at a $4.63 strike was floated, Hillhouse objected, then Hillhouse joined the first tranche on May 21, 2026, and five days later management printed a Q1 FY2026 result that conceded the margin leg of the turn — operating loss margin widened from -4.1% to -9.7% on Douyin traffic-acquisition costs while skincare grew 58.5% and gross margin set a record 80.2%. The ADS sits at US$3.17 (June 18, 2026), -46% over the trailing three months, and well below the $4.63 strike at which the founder, Trustar, and Hillhouse all wrote checks sixty days ago. The page below is the bridge from that recent re-priced setup to the next data points that update the multi-year skincare-platform thesis — not a verdict on whether the long thesis is right.

Variant view, sized in numbers, up front

Consensus is thin (1-2 analysts), Buy-rated, with a mean US$6.73 price target and a FY2026E revenue of RMB5,238M (+21.9% YoY, ~$759M) and FY2027E RMB5,710M (+9.0%, ~$828M). Two specific places where this page sits off the Street, sized:

• FY2026 non-GAAP operating margin: consensus implicitly modeling break-even to +1%; we model -2% to -4%. Q1 FY2026's non-GAAP operating margin was -8.3% and management explicitly chose to "selectively deploy resources" on Douyin traffic in Q2 [1]. Even if Q2-Q4 average -1% (heroic on the Q1 starting point), the full-year clears -3%. Implied delta to consensus: -3 to -5 percentage points of operating margin, or roughly RMB160-260M of "missing" non-GAAP EBIT vs the Street's implied trajectory.
• FY2027 revenue: consensus +9.0% YoY; we sit closer to +12-15% on a skincare-mix arithmetic that has grown the Skincare segment +58.5% / +83.2% / +78.7% / +47.5% across the last four printed quarters — even decelerating sharply, +12-15% is the conservative read. Implied delta to consensus: +RMB180-340M of revenue, but the operating leverage from that revenue is the unresolved question, not the top line.

Stated bluntly: we agree with the bulls on the size of the prize and the gross-margin durability; we disagree with the implied Street margin glide and think the next two prints close that gap down, not up. The page is built around that variant.

What just happened — the recent setup in three movements

The last six months are one tightly-linked sequence, not three independent events. Read in this order:

1. March 11, 2026 — the related-party convertible is announced. Yatsen signed a Note Purchase Agreement with Polaris Veritas, a vehicle affiliated with Trustar Capital and CEO Jinfeng Huang himself, for approximately US$120M of RMB-denominated convertible senior notes in two equal tranches, plus warrants on Class A shares, at a US$4.63 ADS conversion price, 1.5% coupon, with a 4% IRR put floor on the third anniversary of the First Note and warrants struck at the equivalent of US$10.00 per ADS [2]. The structure is the most overt governance friction in the public record: the founder is the lender, the founder benefits from the put, and the founder still controls 90.7% of votes from 34.3% of economics. The market read this exactly as it was — a related-party self-deal at a 46%-premium strike — and the stock has not recovered since.

2. April 29, 2026 — the FY2025 20-F discloses a significant-shareholder objection. The filing flags that "a significant shareholder of ours raised objections to, and concerns regarding, the consummation of the transaction" and was negotiating to participate; the first tranche had not yet closed as of the 20-F's filing date [2]. The market was left to wonder whether the deal would close at all.

3. May 21, 2026 — Hillhouse joins; first tranche closes. Management confirmed on the Q1 FY2026 call that the private placement of convertible notes and warrants completed on May 21, 2026 with Trustar, Hillhouse and the founder participating [3]. Hillhouse — the largest outside holder at 13.8% — is now also an inside party in the same instrument. The first overhang resolved, the second (Tranche 2 close) opened, and the dilution math (~26M ADSs at full conversion, +10% warrants on top) became real.

4. May 26, 2026 — Q1 FY2026 print resets the margin story. Revenue +22.5% to RMB1.02B (in line with the prior guide), Skincare +58.5%, gross margin a record 80.2% — and operating loss widened from -4.1% to -9.7% as Selling & Marketing rose to 72.2% of revenue (from 66.4%) on "higher traffic acquisition costs on the Douyin platform" [1]. Non-GAAP net income swung from +RMB7.1M (Q1 FY25) to -RMB57.3M (Q1 FY26) [4]. Q2 FY2026 guidance: RMB1.20-1.30B (+10-20%), a deceleration from the +22.5% just printed [5].

The cleanest summary the tape gives: the convertible saga and Q1 FY2026 each reduced the option-value premium that had floated the stock through 2025. Together they took the ADS from US$5.85 at end-March to US$3.17 today (-46%), with the Hillhouse-joins headline treated by the market as confirmation the founder needed the money, not as endorsement.

Historical earnings price-reaction base rate — what magnitude looks like here

Earnings is the dominant single-event mover for YSG, and the tape has been highly directional. Across the last 10 prints (Q4 FY23 → Q1 FY26), the average absolute one-day move (T-1 close → T+1 close) is 13.3%, with a range of 4.3% (Q2 FY24) to 27.9% (Q1 FY24). Six of ten reactions were declines. This base rate is what "High impact" actually means on this name — it is not 2-4%, it is ±10-15%, with tail outcomes near ±25%.

Two practical takeaways. First, the cleanest pattern is strong rally going into the print → negative reaction even on a beat (Q3 FY25, Q1 FY25, Q4 FY24 are the textbook examples). Second, the directional bar is on margin/guidance, not the headline revenue number — Q1 FY26 beat on revenue and rallied +12% even on a worse-than-feared op-margin print, because the trading positioning was already washed-out and the headline guide (+10-20%) was inside the range. So sizing "High impact" reactions on this name as ±10-15% with skew toward downside whenever the stock has rallied >15% in the trailing month is a defensible prior.

The live debate — what the market is actively watching

There are four arguments running through the tape right now. Each carries a confirming and a challenging tell.

The single load-bearing question is #4 — S&M intensity. As the Long-Term Thesis tab framed it: a wide-moat consumer brand does not see its operating margin set quarter-by-quarter by a third-party platform. Q1 FY2026 said yes it does; Q2 FY2026 says whether that was the run rate.

Ranked catalyst timeline — by decision value, not by date

Five catalysts inside the next ~6 months that could move the underwriting debate. Ranked by expected decision value to a hedge-fund PM, with magnitude sized to the 10-print earnings base rate above and to the bull/bear scenario gap.

The Q2 FY2026 earnings date (Aug 20, 2026) is consistent with the yfinance earnings calendar and the company's historical Q2 cadence (Q2 FY24: Aug 20, Q2 FY25: Aug 21). The convertible second-tranche window and 4% IRR put floor are anchored in the FY2025 20-F subsequent-events note [2], and the buyback program runs through May 16, 2027 per the FY2025 20-F repurchase disclosure [6].

The ranking choice. Q2 FY2026 (Aug 20) is #1 because it is the first observable test of the platform-pricing mechanic that broke the Q1 narrative, on a hard date inside 90 days, on an asymmetric-down setup. The second tranche of the convertible is #2 because the strike and counterparty composition update the governance read directly — and the bear read of a repricing is the highest-magnitude downside catalyst between now and year-end. The FY2026 20-F (Q4 FY2026 print) sits at #3 even though it is ~9 months out: it is the single disclosure that resolves whether the FY2025 turn was an inflection or a head-fake at segment level, and no smaller print between now and then can substitute. Q3 FY2026 is the second data point on Douyin TAC — the value depends entirely on what Q2 prints. Buyback execution is in the table for completeness but does not move the underwriting case at $30M / 24-month pace.

Impact / decision view — which events actually resolve the debate

The catalyst table ranks decision value; this table separates information from resolution. Only two events between now and the FY2026 20-F can actually close the underwriting debate; the rest add data points to a still-open question.

The decision read: between now and year-end 2026, only Q2 FY2026 and the convertible second-tranche close are inside the typical 6-month catalyst lens. The single most thesis-resolving event of the entire cycle — Skincare segment OI in the FY2026 20-F — sits 9 months out, well outside the standard catalyst window. That is itself a finding: PMs trying to underwrite YSG inside a 6-month horizon are buying two near-term data points that update the thesis, not one that resolves it.

Next 90 days — the focused watchlist

What would change the view

Three observable signals, in priority order. These are the things that would force a multi-year thesis update — Bull, Bear, Moat, Forensic. This is the event path, not a verdict.

References

1. Yatsen Holding Limited — Q1 FY2026 Earnings Release, Operating Expenses and Douyin TAC commentary — p.2
2. Yatsen Holding Limited — FY2025 Annual Report (Form 20-F), Note 23 Subsequent Events — March 2026 Convertible Note Purchase Agreement terms, 4% IRR put floor, NDRC certificate and significant-shareholder objection — p.226
3. Yatsen Holding Limited — Q1 FY2026 Earnings Release, CEO commentary on May 21, 2026 first-tranche closing with Trustar, Hillhouse and the founder — p.1
4. Yatsen Holding Limited — Q1 FY2026 Earnings Release, Net Loss / Non-GAAP Net Loss detail — p.3
5. Yatsen Holding Limited — Q1 FY2026 Earnings Release, Q2 FY2026 Business Outlook (RMB1.20-1.30B, +10-20% YoY) — p.4
6. Yatsen Holding Limited — FY2025 Annual Report (Form 20-F), Item 3.D Risk Factors — May 16, 2025 $30M share repurchase program over 24 months — p.69